GSK boss rethinking R&D incentives, as Barron and Sin seek out early and late-stage ops

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Apr 25, 2018 at 1:22 PM.

  1. #1 cafead, Apr 25, 2018 at 1:22 PM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via GlaxoSmithKline CEO Emma Walmsley has been in the hot seat for around a year, and while announcing the company's first-quarter results this week had new CSO Hal Barron by her side, as the two hinted at possible changes in R&D incentives, and what another new hire made last week could bring to the pipeline.

    article source
     
    Quote

Reply to Thread